- Home
- FEMY vs IPA Comparison
FEMY vs IPA Comparison
Compare FEMY & IPA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FEMY
- IPA
- Stock Information
- Founded
- FEMY 2004
- IPA 1983
- Country
- FEMY United States
- IPA Canada
- Employees
- FEMY N/A
- IPA N/A
- Industry
- FEMY Medical/Dental Instruments
- IPA Biotechnology: Pharmaceutical Preparations
- Sector
- FEMY Health Care
- IPA Health Care
- Exchange
- FEMY Nasdaq
- IPA Nasdaq
- Market Cap
- FEMY 26.0M
- IPA 19.9M
- IPO Year
- FEMY 2021
- IPA 2017
- Fundamental
- Price
- FEMY $1.22
- IPA $0.54
- Analyst Decision
- FEMY Strong Buy
- IPA Strong Buy
- Analyst Count
- FEMY 3
- IPA 2
- Target Price
- FEMY $10.67
- IPA $6.00
- AVG Volume (30 Days)
- FEMY 105.5K
- IPA 316.7K
- Earning Date
- FEMY 11-12-2024
- IPA 12-12-2024
- Dividend Yield
- FEMY N/A
- IPA N/A
- EPS Growth
- FEMY N/A
- IPA N/A
- EPS
- FEMY N/A
- IPA N/A
- Revenue
- FEMY $950,096.00
- IPA $17,441,886.00
- Revenue This Year
- FEMY $135.27
- IPA $4.33
- Revenue Next Year
- FEMY $310.75
- IPA $35.64
- P/E Ratio
- FEMY N/A
- IPA N/A
- Revenue Growth
- FEMY N/A
- IPA 11.21
- 52 Week Low
- FEMY $0.73
- IPA $0.46
- 52 Week High
- FEMY $2.40
- IPA $2.60
- Technical
- Relative Strength Index (RSI)
- FEMY 61.92
- IPA 36.16
- Support Level
- FEMY $1.07
- IPA $0.56
- Resistance Level
- FEMY $1.17
- IPA $0.65
- Average True Range (ATR)
- FEMY 0.05
- IPA 0.06
- MACD
- FEMY 0.01
- IPA -0.00
- Stochastic Oscillator
- FEMY 83.33
- IPA 34.15
About FEMY Femasys Inc.
Femasys Inc is a biomedical company focused on transforming women's healthcare by developing solutions and advancements providing clinical impact to address severely underserved areas. The company's mission is to provide women with minimally invasive, non-surgical product technologies, accessible in the office, improving patient care and overall health economics.
About IPA ImmunoPrecise Antibodies Ltd.
ImmunoPrecise Antibodies Ltd is a supplier of custom antibodies to the research industry and industrial community. The company has aggregated its operations into one reportable segment, Antibody Production, and Related Services. It operates in three principal geographical areas - the United States of America, Canada, Europe, Australia and others. The majority of its revenue is derived from United States of America.